Lumpy Skin Disease in 2026: Why the Goatpox Vaccine Isn't Enough

Lumpy Skin Disease (LSD) continues to pose a significant threat to dairy farming and cattle health across India. For years, veterinarians and state animal husbandry departments have relied on heterologous vaccines—specifically the goatpox vaccine (Uttarkashi strain)—to provide cross-protection against LSD.

However, a breakthrough study published in a leading Springer journal in April 2026 has confirmed what many field veterinarians suspected: the Uttarkashi-strain goatpox vaccine provides inadequate long-term immunity against modern LSD variants.

This finding is causing a surge in searches among farmers looking for answers on how to protect their herds. Here is the scientific reality, symptoms to watch out for, and the vaccine that actually works.

The Problem with the Goatpox Vaccine in 2026

Heterologous vaccination (using a related virus like goatpox to vaccinate against lumpy skin disease) was a valuable stop-gap emergency measure during the massive 2022–2023 outbreaks. It saved millions of animals.

However, the April 2026 research indicates that the evolutionary drift of the LSD virus in South Asia has reduced the cross-protective efficacy of the Uttarkashi strain. Cattle immunized with goatpox are showing breakdown immunity, experiencing mild-to-severe symptoms when exposed to current field strains.

The Solution: Lumpi-ProVacInd

India's scientific community anticipated this limitation. ICAR-IVRI (Indian Veterinary Research Institute) and ICAR-NRCE (National Research Centre on Equines) developed Lumpi-ProVacInd—a homologous, live-attenuated vaccine made specifically from the lumpy skin disease virus.

• Superior Protection: Lumpi-ProVacInd triggers high levels of neutralizing antibodies specific to LSD, providing robust, long-lasting immunity.
• Safety: Safe for pregnant cows and young calves.
• Availability: State veterinary departments are actively transitioning their procurement to Lumpi-ProVacInd in mid-2026.